Xiankangda Group Secures Tens of Millions RMB in Pre-A Funding to Advance Cell Therapy Drug Development
Signing Ceremony for Xiankangda Group’s Equity Investment (Image provided by the company)
VCBeat News learned that on June 6, Xiankangda Group announced that its parent company, Guangdong Xiankangda Biotechnology Co., Ltd., had completed a Pre-A financing round worth tens of millions of RMB. The round was exclusively invested by a fund under Guangdong Lianjing Investment Group Co., Ltd. (hereinafter referred to as “Lianjing Investment”). The funds raised will be primarily used for team building and advancing the company’s existing R&D pipeline.
Mr. Yuan Dezong, the head of Lianjing Investment, is a flagship figure in the investment community. With many years of experience in financial investment and extensive expertise in project investment decision-making, he is one of the five major shareholders of Everbright Securities and has been hailed as the “Dongguan Buffett.”
Mr. Yuan Dezong stated“Over the next decade, new-generation information technology, biotechnology, and new energy will emerge as China’s three leading industries on the global stage, representing the sectors with the most promising growth prospects at present. As an emerging pioneer in the field of biotechnology, Xiankangda Group boasts a clear development strategy, efficient organizational operations, and multiple proprietary platform technologies. We are confident that, through the relentless efforts of its founding team and scientific experts, Xiankangda Group will surely grow into a leader in the field of cell therapy, bringing safer and more effective novel therapeutic options to a broader patient population.”
Mr. Xie Haitao, Founder and Chairman of Xiankangda Group, stated“Mr. Yuan Dezong is an investment master with exceptional strategic vision. The successful conclusion of this collaboration not only demonstrates Lianjing Investment’s recognition of Xiankangda’s R&D strength and industrialization capabilities, but also signifies public confidence in Xiankangda’s value creation and broad market prospects in the field of cell therapy. This round of financing will accelerate Xiankangda’s development of cell-based drugs, hasten the market launch of its products to meet substantial clinical needs, and benefit a wide range of patients.”
Xiankangda Group is a national high-tech enterprise integrating cell storage, research and development, production, and promotion. With cell technology as its core, the company has built an industrial cluster encompassing cell storage, cell-based drug R&D, regenerative medicine, and cell-derived products, covering the upstream, midstream, and downstream segments of the cell industry to create a complete ecosystem.
The Group has more than 10 controlled subsidiaries, nearly 100 professional technical personnel, and has filed over 100 patent applications. It has successfully developed two technology platforms with independent intellectual property rights: Trans-CARTM、Boost-CARTM. Clinical studies of CAR-T therapy targeting solid tumors, including CLDN18.2, GCC, and GPC3, have been conducted at multiple Grade A tertiary hospitals in China, with preliminary data demonstrating manageable safety profiles and favorable clinical efficacy.
Lianjing Investment was founded by Mr. Yuan Dezong in 2011, primarily engaging in industrial investment, investment in and management of high-tech industries, as well as corporate investment planning and consulting. Under the leadership of Mr. Yuan, Lianjing Investment has invested in numerous enterprises in strategic emerging industries.